Workflow
Multi - drug resistant pathogens
icon
Search documents
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
Globenewswire· 2025-08-05 11:00
-- Launch of ORLYNVAH Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. "We are on track to launch ORLYNVAH™ this m ...